Scientific Consulting Services返回科学咨询服务

GENMABS · TREATMENT BENEFIT RESEARCH健脉 · 治疗获益研究

Treatment Benefit Analysis治疗获益分析

Compare treatment strategies. Investigate who may benefit. We assess whether clinical and molecular data support the research question, then develop and evaluate models with explicit uncertainty and limitations.比较治疗方案,研究哪些患者可能获益。先评估临床与分子数据能否支持研究问题,再开发和评估模型,明确呈现不确定性与限制。

THE FRAMEWORK研究流程框架

From data to scientific evidence从原始数据到科学证据

Explore completed research stages and the current validation status. The report separates measured results from claims that still require evidence.点击查看已完成的研究阶段和当前验证状态;报告将实际结果与尚待证实的结论分开呈现。

Stages 1–3 and the evidence report show completed research work. Stage 4 describes the validation boundary. These are inspectable case materials, not an automated patient treatment recommender.第1–3阶段及证据报告展示已完成的研究工作;第4阶段说明验证边界。这些是可查阅的案例材料,不是自动患者用药推荐系统。

STAGE 01 · AVAILABLE NOW第一阶段 · 现可展示

What we've already demonstrated已完成的研究案例与可复用能力

Two independent public-data feasibility and modeling projects show how our analysis moves from data review to a defensible go/no-go decision. These are research examples, not clinical treatment products.两项基于公开数据的研究展示了从数据审查到可解释 GO/NO-GO 判断的分析过程。这些是研究案例,不是临床用药推荐产品。

PROGNOSTIC MODELING预后建模2026.10

TCGA-LUAD + GSE72094

333Development cohort开发队列
393External cohort外部队列

Clinical and molecular data harmonization, four-model comparison, repeated nested cross-validation, and exploratory external validation of two models.整合临床与分子数据,比较四种模型,进行重复嵌套交叉验证,并对其中两个模型完成探索性外部检验。

Result: This prespecified molecular panel did not show reliable incremental prognostic value over the clinical baseline.结论:本轮预先指定的分子面板未显示超越临床模型的稳定增量预后价值。
Sample PDF report查看示例PDF报告 ↗
TREATMENT DATA FEASIBILITY治疗数据可行性2026.10

MSK-CHORD NSCLC非小细胞肺癌

7,809NSCLC screened初始NSCLC筛查
625Main feasibility cohort主可行性队列

Patient-level audit of clinical, genomic, treatment, and timeline variables; biology-guided pathway-state design and eligibility screening for two treatment strategies.审查患者级临床、基因组、治疗与时间线变量;依据生物机制设计通路状态,筛查两种治疗方案的可比较患者。

Result: Limited GO for a low-dimensional feasibility study; NO-GO for individual treatment-benefit claims at this stage.结论:可有限开展低维探索;现阶段不支持个体化治疗获益预测或临床推荐。
Sample PDF report查看示例PDF报告 ↗

The 625-person MSK example above is an earlier pathway/chemotherapy feasibility analysis. The PD-L1 × ICI study below uses a separately defined 489-person LUAD cohort; the two denominators and treatment comparisons are not interchangeable.上方625人MSK案例是早期通路/化疗可行性研究;下方PD-L1×ICI研究使用另行定义的489人肺腺癌队列,两者人数与治疗比较不可互换。

Continue to the PD-L1 study ↓继续查看PD-L1研究 ↓

ILLUSTRATIVE RAW INPUT原始数据结构示例

patient_id | drug_name | start_date
case_001 | regimen A | 2024-01-10
case_001 | regimen B | missing

RESEARCH-READY OUTPUT研究就绪矩阵示例

patient_id | index_date | exposure | qc_flag
case_001 | 2024-01-10 | reviewed | check

Illustrative synthetic rows above—not actual patient records. Raw datasets are not uploaded on this webpage.上方仅为合成示例,不是真实患者记录。本页面不会接收原始患者数据上传。

02 · MSK-CHORD LUAD02 · MSK-CHORD 肺腺癌

Biological Design生物学特征设计

A mechanism-informed biomarker choice, translated into explicit patient-level definitions.从生物机制选择标志物,再转化为明确的患者级变量定义。

Tumor / immune interface肿瘤与免疫细胞界面

PD-L1 on tumor cells can bind PD-1 on T cells and suppress T-cell activity. Anti-PD-1 or anti-PD-L1 antibodies can interrupt this checkpoint interaction.肿瘤细胞上的PD-L1可与T细胞上的PD-1结合,抑制T细胞活性。抗PD-1或抗PD-L1抗体可阻断这一免疫检查点相互作用。

Measured feature: PD-L1本轮测量特征:PD-L1

The model uses the latest documented tumor-cell PD-L1 positive/negative result on or before the treatment index date. It does not measure PD-1 expression, a mutation-defined pathway state, or the entire pathway’s activity.模型使用治疗开始当日或之前最近一次记录的肿瘤细胞PD-L1阳性/阴性结果。它不是PD-1表达、由突变定义的通路状态,也不是完整通路活性。

The recorded ICI category pools checkpoint agents and combinations; it is not limited to one anti-PD-L1 antibody. Not every ICI directly targets the PD-1/PD-L1 binding interface.本轮ICI类别合并了多种检查点药物及联合用药,不限于一种抗PD-L1单抗;并非所有ICI都直接作用于PD-1/PD-L1结合界面。

P · BiomarkerP · 标志物

Recorded positive vs negative; measured before index treatment. Missing is not negative. No common TPS threshold is imposed on heterogeneous source reports.使用治疗前报告的阳性或阴性;缺失不当作阴性。不同来源报告不强行套用统一TPS阈值。

T · TreatmentT · 治疗

Any named ICI within the 28-day initiation window vs none recorded in that window. This is not an ever/never ICI comparison.起始28天窗口内记录已命名ICI,与该窗口未记录ICI比较;不是整个随访期间曾用/从未用ICI。

P × T · HypothesisP × T · 研究假设

Does the ICI-associated relative hazard differ by pretreatment PD-L1 status? An interaction is a hypothesis to test, not proof of patient-level benefit.ICI相关相对死亡风险是否随治疗前PD-L1状态变化?交互项用于检验假设,本身不证明个体获益。

PD-L1 negativity does not mean that cancer arose through a different single pathway, and PD-L1 positivity does not guarantee response. RTK/RAS/MAPK or PI3K mutations are not direct measurements of checkpoint blockade sensitivity.PD-L1阴性不代表肿瘤由另一条特定通路引起,阳性也不保证响应。RTK/RAS/MAPK或PI3K突变不能直接等同于免疫检查点阻断敏感性。

Cohort timing and treatment boundaries队列时序与治疗边界

Documented stage IV LUAD before index; entry by the landmark; pretreatment PD-L1; no targeted drug/ADC recorded in the index window; observed beyond index + 28 days. OS is remaining survival from that landmark. Patients without ICI may still have chemotherapy, research agents, or other therapies.治疗前记录为IV期肺腺癌;患者在landmark前进入观察;PD-L1在治疗前;起始窗口排除记录靶向药/ADC者;观察超过治疗开始后28天。OS从该landmark计算剩余生存。未记录ICI者仍可能接受化疗、试验药或其他治疗。

The current 489-person cohort is not the earlier 625-person feasibility cohort. It does not require an identical chemotherapy backbone, so it cannot isolate an add-on ICI effect.当前489人不是早期625人可行性队列。本轮没有要求相同化疗基础,因此不能单独识别“增加ICI”的效应。

Biology reference: NCI · Immune Checkpoint Inhibitors ↗机制参考:NCI · 免疫检查点抑制剂 ↗

03 · MSK-CHORD LUAD03 · MSK-CHORD 肺腺癌

Model Development模型开发

Five model comparisons separate clinical risk, biomarker information, treatment exposure, and their interaction.五模型比较分别考察临床风险、标志物信息、治疗记录及其交互。

Model模型Inputs输入Question比较内容
M1CClinical and background-treatment baseline临床及背景治疗基线
M2C + PBaseline + pretreatment tumor PD-L1基线 + 治疗前肿瘤PD-L1
M3C + TBaseline + index-window ICI exposure基线 + 起始窗口ICI记录
M4C + P + TBoth main effects; no interaction同时加入两个主效应,无交互
M5C + P + T + P × TMain effects + biomarker–treatment interaction主效应 + 标志物与治疗交互

C = expanded clinical/background-treatment baseline; P = pretreatment PD-L1; T = named ICI in the initiation window. P and T are excluded from C.C为扩展临床/背景治疗基线;P为治疗前PD-L1;T为起始窗口已命名ICI。C中不含P和T。

Same patients同一批患者

489 patients · 302 deaths · 187 censored. The same eligibility rules and fold assignments apply to M1–M5.489人 · 302例死亡 · 187人删失。M1–M5使用同一入组规则和交叉验证分折。

Fixed model specification固定模型设置

Ridge Cox, alpha = 1; Breslow ties. Standardization and missing-value handling use training folds only. No tuning to obtain a smaller p-value.Ridge Cox,alpha=1,Breslow并列处理。标准化与缺失处理仅在训练折估计;不为降低p值调参。

Internal evaluation内部评估

Event-stratified 5-fold cross-validation, repeated 3 times. Out-of-fold discrimination and IPCW prediction error; calibration from the first repeat.按事件分层的5折交叉验证,重复3次。使用折外预测计算区分度和IPCW误差;校准采用首轮折外预测。

What is actually in baseline C?基线C具体包含什么?

Sex; ECOG categories and missingness; liver/brain site documentation in the 90 days before index; log(1 + documented extra-pulmonary site categories); no-site-documentation indicator; outside-MSK prior-treatment documentation within 365 days and missingness; cisplatin indicator in the initiation window. Histology is constant in this LUAD-only cohort and is dropped.性别;ECOG分类及缺失;治疗前90天肝/脑部位文档;log(1+已记录肺外部位类别数);无部位文档标记;治疗前365天院外既往治疗文档及缺失;起始窗口顺铂指示。组织学因全体为肺腺癌而为常数,被剔除。

No positive site record is not proof of no metastasis. The cisplatin indicator is not full adjustment for chemotherapy. Current age, undated smoking summaries and post-treatment laboratory results are not included.没有阳性部位文档不等于没有转移;顺铂指示不能完整控制化疗差异。本轮未纳入当前年龄、无日期的吸烟汇总和治疗后血液指标。

04 · MSK-CHORD LUAD04 · MSK-CHORD 肺腺癌

Model Validation模型验证

Internal evaluation completed. External validation of the original PD-L1 × ICI model remains outstanding.内部评估已完成。原PD-L1×ICI模型的外部验证仍待完成。

Completed · Internal已完成 · 内部验证

Repeated out-of-fold evaluation, calibration review, paired conditional bootstrap comparisons, and an exploratory interaction analysis. These assess performance within the development source.已完成重复折外评估、校准审查、配对条件bootstrap比较及探索性交互分析;这些属于开发数据来源内部的评估。

Pending · Original-model external待完成 · 原模型外部验证

An independent cohort still needs compatible pretreatment PD-L1, clinical inputs, treatment definitions and OS timing. We do not label the current model externally validated.仍需要治疗前PD-L1、临床输入、治疗定义和OS起点兼容的独立队列。目前不标注本模型已获外部验证。

Separate transfer assessment: what it can and cannot establish另行开展的迁移评估:能说明什么?

Two independent published trial datasets were used for a newly simplified sex/ECOG prognostic model. Its discrimination and calibration were limited. It omits PD-L1 and its treatment interaction, and the trial treatment contrast differs from this cohort.另用两个已发表试验数据集测试了新建的性别/ECOG简化预后模型,区分度和校准均有限。该模型不含PD-L1及其治疗交互,试验治疗比较也与当前队列不同。

That work is a separate transferability assessment, not external validation of the five models shown here. No external interaction p-value or validated patient-level benefit is claimed.该工作属于另行开展的可迁移性评估,不是这里五个模型的外部验证。本页面不宣称外部交互p值或经验证的患者级治疗获益。

05 · OUTPUT · MSK-CHORD LUAD05 · OUTPUT · MSK-CHORD 肺腺癌

Scientific Evidence Report科学证据报告

The result is an auditable research finding, with uncertainty and limitations presented alongside the measured performance.将实际性能、统计不确定性和限制一同呈现,形成可审计的研究结论。

0.60610.6061

M5 mean internal C-index. M1: 0.5994. The improvement is small.M5内部平均C-index;M1为0.5994。增量较小。

+0.0082+0.0082

Mean ΔC, M5 − M4. The first-repeat paired interval crosses zero.M5−M4平均ΔC;首轮配对增量区间跨0。

External validation pending外部验证待完成

Exploratory evidence report available; a validated individual treatment-benefit model has not been established.可交付探索性证据报告;尚未建立经验证的个体治疗获益模型。

Primary C1 baseline · identical 489 patients across all models主分析C1基线 · 所有模型使用相同489人
Model模型C-index ↑Brier 12m ↓Brier 24m ↓Calibration slope 24m*24月校准斜率*
M10.59940.22010.24460.553
M20.60010.21600.24080.596
M30.59730.22080.24530.547
M40.59790.21670.24140.592
M50.60610.21390.23670.668

C-index and Brier: means over three repeats. *Calibration slopes: first-repeat 24-month IPCW logistic estimates; ideal slope = 1. These are internal results, not external performance.C-index和Brier为三次重复均值。*校准斜率为首轮24月IPCW逻辑校准估计,理想值为1。全部为内部评估,不是外部性能。

What the evidence supports目前证据支持什么

An exploratory adjusted PD-L1 × ICI hazard interaction was observed (Wald p = 0.0099). Predictive improvement remains modest and uncertain. This is an observational association, not proof that ICI benefits or harms a particular patient.观察到探索性调整后的PD-L1×ICI风险交互(Wald p=0.0099)。预测增量仍较小且不确定。这是观察性关联,不证明ICI使某位患者获益或受害。

The detailed report includes the four-cell audit, exact definitions, model comparison, calibration, uncertainty, limitations and source references. Only aggregate results are downloadable here.详细报告包含四格审计、精确定义、模型比较、校准、不确定性、限制和参考来源。此处仅提供汇总结果下载。

BEFORE A PROJECT开始项目之前

What a first review examines初步审查哪些信息

We first define the decision, check the structure and limitations of the available dataset, and agree on a realistic scope and deliverables.我们首先明确需要回答的研究决策,审查数据结构和限制,再确定合理的分析范围及交付成果。

01

Cohort & IDs队列与标识符Patient/sample linkage, duplicates, inclusion criteria.患者与样本对应、重复记录、入组标准。

02

Clinical & molecular variables临床与分子变量Definitions, missingness, assay availability, timing.变量定义、缺失率、检测覆盖和测量时间。

03

Treatment & outcomes治疗与结局A/B definitions, follow-up, events, confounding and overlap.A/B定义、随访、事件、混杂与重叠性。

04

Decision-ready report决策支持报告What is supported, what is uncertain, and what data are needed next.哪些结论受支持、哪些仍不确定以及下一步数据需求。

START WITH THE QUESTION从研究问题开始

Need to assess your data?需要评估你的研究数据吗?

Share a brief, non-identifying description of your research question and available data. We will discuss the proposed review scope before any secure data transfer.请先介绍不含患者身份信息的研究问题及可用数据概况。确认项目范围及安全交付要求之后,再讨论数据传输。

Request Data Assessment申请数据可行性评估 ↗

For research use. No direct patient care recommendations. Do not email identifiable health records or upload PHI through this page.Public-source analyses do not imply endorsement by NIH, NCI, TCGA, MSK, or GEO.仅供科研使用,不提供直接临床用药推荐。请勿通过此页面或普通邮件发送可识别患者健康信息。公共数据分析不代表 NIH、NCI、TCGA、MSK 或 GEO 背书。